Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2023 Earnings Call Transcript

Adam Townsend: Yes, thanks. Hey, Joey. So no surprise, take out vasculitis from the conversation for a second. Every launch has a subset of physician population that I would deem as laggards. Those that it’s a technical term. They wait to see what happens with the drug once it launches. They follow key opinion leaders, they follow that experience. It doesn’t matter if you’re launching a drug in the retina or launching a drug in another space, that subset of physician population exists. It’s the same within this launch, right? So we had physicians who said I would wait for the permanent J-code. We’ve had physicians who said I want to see that Professor X or Doctor Y is using and has good experience before I start. So as we get through the launch trajectory, we expect to unlock all of those segments.

As those physicians who are waiting will get the check in the box that they need to say, I’ve seen enough, I understand this now, my colleagues are using, I’m going to start to use it. So it’s a future opportunity. I think we’ll continue to make inroads within that segment.

Joseph Stringer: Great. Thank you for taking our question.

Cedric Francois: Thank you, Joey.

Operator: Thank you. And I see no further questions in the Q&A queue at this time. I will now turn the call back over to Dr. Cedric Francois for any closing remarks.

Cedric Francois: Thank you so much. Well, in closing, thank you all for joining us today. We are around later today and tomorrow. If you have any additional questions, feel free to reach out to Meredith. Thank you again and have a wonderful day.

Operator: Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.